UNH Stock Analysis: UnitedHealth | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 365.025m USD | 12M Return: 17.2% | US91324P1021 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.15B
EPS Trend: -75.1%
Qual. Beats: 3
Rev. Trend: 98.1%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UnitedHealth Group (NYSE: UNH) is a U.S.-based health care company operating across four business segments organized under two main platforms: Optum (Optum Health, Optum Insight, and Optum Rx) and UnitedHealthcare. The company is a vertically integrated player in the managed care sector, pairing health plan administration and insurance products with its own pharmacy benefit management, care delivery, and health care analytics businesses. UNH is one of the largest constituents of the GICS Managed Health Care sub-industry.
The three Optum segments handle care delivery and consumer engagement (Optum Health), software, consulting and outsourcing for providers, plans and life sciences firms (Optum Insight), and pharmacy care services including retail network contracting, home delivery, specialty pharmacy, infusion, and clinical programs such as formulary management and drug therapy management (Optum Rx).
The UnitedHealthcare segment sells consumer-oriented health benefit products and serves national, mid-sized and small employers, as well as individuals and public-sector clients. Its offerings include Medicaid managed care products (such as TANF, CHIP, DSNPs and Aged, Blind, and Disabled programs) and other state and community programs aimed at economically disadvantaged and medically underserved populations.
UnitedHealth Group was founded in 1974 and is headquartered in Eden Prairie, Minnesota. Its common stock trades on the NYSE under the ticker UNH and is classified as a mega-cap security within the Health Care sector.
- Optum Health expands care delivery and value-based contracts
- Optum Rx pharmacy margins pressured by GLP-1 drug costs
- Medicare Advantage Star ratings drive UnitedHealthcare enrollment and revenue
| Net Income: 15.9b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.79 > 1.0 |
| NWC/Revenue: -6.73% < 20% (prev -4.70%; Δ -2.02% < -1%) |
| CFO/TA 0.08 > 3% & CFO 26.2b > Net Income 15.9b |
| Net Debt (45.8b) to EBITDA (28.0b): 1.64 < 3 |
| Current Ratio: 0.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (902.0m) vs 12m ago -1.10% < -2% |
| Gross Margin: 22.81% > 18% (prev 19.70%; Δ 3.11% > 0.5%) |
| Asset Turnover: 143.2% > 50% (prev 138.0%; Δ 5.16% > 0%) |
| Interest Coverage Ratio: 6.16 > 6 (EBIT TTM 23.7b / Interest Expense TTM 3.85b) |
| A: -0.10 (Total Current Assets 85.6b - Total Current Liabilities 116b) / Total Assets 313b |
| B: 0.31 (Retained Earnings 95.6b / Total Assets 313b) |
| C: 0.08 (EBIT TTM 23.7b / Avg Total Assets 314b) |
| D: 0.50 (Book Value of Equity 104b / Total Liabilities 207b) |
| Altman-Z'' = 1.40 = BB |
| DSRI: 0.36 (Receivables 20.5b/55.4b, Revenue 450b/435b) |
| GMI: 0.86 (GM 19.70% / 22.81%) |
| AQI: 1.04 (AQ_t 0.69 / AQ_t-1 0.66) |
| SGI: 1.03 (Revenue 450b / 435b) |
| TATA: -0.03 (NI 15.9b - CFO 26.2b) / TA 313b) |
| Beneish M = -3.63 (Cap -4..+1) = AAA |
As of October 22, 2026, the stock is trading at USD 417.00 with a total of 3,985,793 shares traded. Over the past week, the price has changed by +5.40%, over one month by +10.45%, over three months by -3.85% and over the past year by +17.17%.
Current recommended Stop Loss: 402.50 (which is 3.5% or 1.2 ATR below the current price).
UnitedHealth has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy UNH.
- StrongBuy: 15
- Buy: 7
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 477 | 14.4% |
P/E Trailing = 26.1524
P/E Forward = 16.5837
P/S = 0.8111
P/B = 3.4004
P/EG = 1.0118
Revenue TTM = 450b USD
EBIT TTM = 23.7b USD
EBITDA TTM = 28.0b USD
Long Term Debt = 72.3b USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.62b USD (from shortTermDebt, last quarter)
Debt = 74.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.8b USD (calculated: Debt 74.3b - CCE 28.5b)
Enterprise Value = 411b USD (365b + Debt 74.3b - CCE 28.5b)
Interest Coverage Ratio = 6.16 (Ebit TTM 23.7b / Interest Expense TTM 3.85b)
EV/FCF = 18.00x (Enterprise Value 411b / FCF TTM 22.8b)
FCF Yield = 5.56% (FCF TTM 22.8b / Enterprise Value 411b)
FCF Margin = 5.08% (FCF TTM 22.8b / Revenue TTM 450b)
Net Margin = 3.53% (Net Income TTM 15.9b / Revenue TTM 450b)
Gross Margin = 22.81% ((Revenue TTM 450b - Cost of Revenue TTM 347b) / Revenue TTM)
Gross Margin QoQ = 19.53% (prev 32.74%)
Tobins Q-Ratio = 1.31 (Enterprise Value 411b / Total Assets 313b)
Interest Expense / Debt = 5.18% (Interest Expense 3.85b / Debt 74.3b)
Taxrate = 15.54% (3.07b / 19.7b)
NOPAT = 20.0b (EBIT 23.7b * (1 - 15.54%))
Current Ratio = 0.74 (Total Current Assets 85.6b / Total Current Liabilities 116b)
Debt / Equity = 0.71 (Debt 74.3b / totalStockholderEquity, last quarter 104b)
Debt / EBITDA = 1.64 (Net Debt 45.8b / EBITDA 28.0b)
Debt / FCF = 2.01 (Net Debt 45.8b / FCF TTM 22.8b)
Total Stockholder Equity = 98.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.06% (Net Income 15.9b / Total Assets 313b)
RoE = 16.10% (Net Income TTM 15.9b / Total Stockholder Equity 98.6b)
RoCE = 13.88% (EBIT 23.7b / Capital Employed (Equity 98.6b + L.T.Debt 72.3b))
RoIC = 11.13% (NOPAT 20.0b / Invested Capital 180b)
WACC = 5.16% (E(365b)/V(439b) * Re(5.32%) + D(74.3b)/V(439b) * Rd(5.18%) * (1-Tc(0.16)))
Discount Rate = 5.32% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.45 | Cagr: -1.26%
[DCF] Terminal Value 77.97% ; FCFF base≈20.6b ; Y1≈23.7b ; Y5≈34.8b
[DCF] Fair Price = 532.9 (EV 524b - Net Debt 45.8b = Equity 478b / Shares 897.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -75.14 | EPS CAGR: -15.47% | SUE: 1.02 | # QB: 3
Revenue Correlation: 98.12 | Revenue CAGR: 8.20% | SUE: 0.88 | # QB: 3
EPS current Quarter (2027-03-31): EPS=8.17 | Chg30d=+0.59% | Revisions=+25% | Analysts=16
EPS current Year (2026-12-31): EPS=20.51 | Chg30d=+3.52% | Revisions=+40% | GrowthEPS=+25.4% | GrowthRev=+0.2%
EPS next Year (2027-12-31): EPS=23.17 | Chg30d=+2.78% | Revisions=+17% | GrowthEPS=+13.0% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +44% (up=5, down=1)